IP Library Granted Patent US 7,968,333
Granted Patent B2
US 7,968,333 · App. 11/894,776 · Granted Jun 28, 2011

Adenovirus vectors containing cell status-specific response elements and methods of use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,968,333
App. No.
11/894,776
Granted
Jun 28, 2011
Kind
B2
Abstract

The present invention provides adenoviral vectors comprising cell status-specific transcriptional regulatory elements which confer cell status-specific transcriptional regulation on an adenoviral gene. A “cell status” is generally a reversible physiological and/or environmental state. The invention further provides compositions and host cells comprising the vectors, as well as methods of using the vectors.

Claims (5)

1. A replication-competent adenovirus vector for selective cytolysis of a cancer target cell comprising an adenovirus gene essential for replication selected from the group consisting of E1A, E1B, and E4, operably linked to both of (1) a cell status-specific transcriptional response element (TRE), wherein the cell status-specific TRE comprises the E2F-1 TRE nucleotides presented as SEQ ID NO:1 and (2) a cell-type specific TRE, wherein the cell-type specific TRE is a PSA-TRE comprising nucleotides about 503 to about 2086 of SEQ ID NO:2 and nucleotides about 5285 to about 5836 of SEQ ID NO:2.

2. The adenovirus vector of claim 1 , wherein said vector further comprises a deletion in E3.

3. The adenovirus vector of claim 1 , further comprising a transgene operably linked to the E2F-1 nucleotides presented as SEQ ID NO:1, wherein the transgene encodes ADP having the sequence presented as SEQ ID NO:8.

4. A composition comprising the replication-competent adenovirus vector of claim 1 and a pharmaceutically acceptable excipient.

5. An isolated host cell comprising the adenovirus vector of claim 1 .

Assignments (3)
CHANGE OF NAME Recorded Nov 9, 2020
From: COLD GENESYS, INC.
To: CG ONCOLOGY, INC.
Reel/Frame 054362/0411 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2010
From: BIOSANTE PHARMACEUTICALS, INC.
To: COLD GENESYS, INC.
Reel/Frame 025470/0885 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2010
From: CELL GENESYS, INC.
To: BIOSANTE PHARMACEUTICALS, INC.
Reel/Frame 023973/0005 →